TY - JOUR
T1 - Stereotactic ablative radiotherapy for small lung tumors with a moderate dose
T2 - Favorable results and low toxicity
AU - Duncker-Rohr, V.
AU - Nestle, U.
AU - Momm, F.
AU - Prokic, V.
AU - Heinemann, F.
AU - Mix, M.
AU - Reusch, J.
AU - Messmer, M. B.
AU - Marschner, N.
AU - Waller, C. F.
AU - Weber, W. A.
AU - Grosu, A. L.
PY - 2013/1
Y1 - 2013/1
N2 - Background: Stereotactic ablative body radiotherapy (SBRT, SABR) is being increasingly applied because of its high local efficacy, e.g., for small lung tumors. However, the optimum dosage is still under discussion. Here, we report data on 45 lung lesions [non-small cell lung cancer (NSCLC) or metastases] in 39 patients treated between 2009 and 2010 by SABR. Patients and methods: SABR was performed with total doses of 35 Gy (5 fractions) or 37.5 Gy (3 fractions) prescribed to the 60% isodose line encompassing the planning target volume. Three-monthly follow-up CT scans were supplemented by FDG-PET/CT if clinically indicated. Results: The median follow-up was 17 months. Local progression-free survival rates were 90.5% (all patients), 95.0% (NSCLC), and 81.8% (metastases) at 1 year. At 2 years, the respective local progression-free survival rates were 80.5%, 95.0%, and 59.7%. Overall survival rates were 71.1% (all patients), 65.4% (NSCLC), and 83.3% (metastases) at 1 year. Overall survival rates at 2 years were 52.7%, 45.9%, and 66.7%, respectively. Acute side effects were mild. Conclusion: With the moderate dose schedule used, well-tolerated SABR led to favorable local tumor control as in other published series. Standardization in reporting the dose prescription for SABR is needed to allow comparison of different series in order to determine optimum dosage.
AB - Background: Stereotactic ablative body radiotherapy (SBRT, SABR) is being increasingly applied because of its high local efficacy, e.g., for small lung tumors. However, the optimum dosage is still under discussion. Here, we report data on 45 lung lesions [non-small cell lung cancer (NSCLC) or metastases] in 39 patients treated between 2009 and 2010 by SABR. Patients and methods: SABR was performed with total doses of 35 Gy (5 fractions) or 37.5 Gy (3 fractions) prescribed to the 60% isodose line encompassing the planning target volume. Three-monthly follow-up CT scans were supplemented by FDG-PET/CT if clinically indicated. Results: The median follow-up was 17 months. Local progression-free survival rates were 90.5% (all patients), 95.0% (NSCLC), and 81.8% (metastases) at 1 year. At 2 years, the respective local progression-free survival rates were 80.5%, 95.0%, and 59.7%. Overall survival rates were 71.1% (all patients), 65.4% (NSCLC), and 83.3% (metastases) at 1 year. Overall survival rates at 2 years were 52.7%, 45.9%, and 66.7%, respectively. Acute side effects were mild. Conclusion: With the moderate dose schedule used, well-tolerated SABR led to favorable local tumor control as in other published series. Standardization in reporting the dose prescription for SABR is needed to allow comparison of different series in order to determine optimum dosage.
KW - Metastasis
KW - Non-small cell lung cancer
KW - Optimum dose schedule
KW - Stereotactic ablative radiotherapy
KW - Toxicity
UR - http://www.scopus.com/inward/record.url?scp=84871748178&partnerID=8YFLogxK
U2 - 10.1007/s00066-012-0224-y
DO - 10.1007/s00066-012-0224-y
M3 - Article
C2 - 23179248
AN - SCOPUS:84871748178
SN - 0179-7158
VL - 189
SP - 33
EP - 40
JO - Strahlentherapie und Onkologie
JF - Strahlentherapie und Onkologie
IS - 1
ER -
